US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6518281B2
(en)
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US6281230B1
(en)
*
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
TR200101501T2
(tr)
*
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı.
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US8030343B2
(en)
*
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US6458810B1
(en)
*
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
US7812169B2
(en)
*
|
2000-11-30 |
2010-10-12 |
The Children's Medical Center Corporation |
Method of synthesis of 4-amino-thalidomide enantiomers
|
CA2439410C
(fr)
*
|
2001-02-27 |
2011-09-06 |
William D. Figg |
Analogues de thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
|
EP1423115B9
(fr)
*
|
2001-08-06 |
2009-09-02 |
The Children's Medical Center Corporation |
Activite antiangiogenetique d'analogues de thalidomide substitues par azote
|
DE60233420D1
(de)
*
|
2001-09-27 |
2009-10-01 |
Equispharm Co Ltd |
Fumagillolderivate und verfahren zu deren herstellung
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
DE60331537D1
(de)
*
|
2002-05-17 |
2010-04-15 |
Celgene Corp |
Kombinationen zur behandlung von multiplem myelom
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
EP1556033A4
(fr)
*
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
Methodes et compositions mettant en oeuvre des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge des cancers et autres maladies
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
CA2501936A1
(fr)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplastiques
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
CN1735412A
(zh)
|
2002-11-06 |
2006-02-15 |
细胞基因公司 |
利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
AU2003294311B8
(en)
*
|
2002-11-18 |
2008-06-05 |
Celgene Corporation |
Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
WO2005028436A2
(fr)
|
2003-09-17 |
2005-03-31 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Analogues du thalidomide
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
AU2004288714A1
(en)
*
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
EP2065383A1
(fr)
|
2003-11-19 |
2009-06-03 |
Signal Pharmaceuticals, Inc. |
Composés d'indazoles et procédés d'utilisation associés en tant qu'inhibiteurs de kinase de protéine
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
EP2505200A1
(fr)
*
|
2004-03-22 |
2012-10-03 |
Celgene Corporation |
Procédé dýutilisation et compositions comprenant des composés immunomodulateurs pour le traitement et la sclérodermie
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
EP1744749A4
(fr)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
Procedes d'utilisation et composition comprenant des composes d'un immunomodulateur, destines au traitement et a la prise en charge de syndromes myelodysplasiques
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
BRPI0510110A
(pt)
*
|
2004-04-23 |
2007-09-25 |
Celgene Corp |
método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
|
CA2579291C
(fr)
*
|
2004-09-03 |
2011-11-29 |
Celgene Corporation |
Procedes de preparation de 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines substituees
|
JP2008518924A
(ja)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物
|
MX2007006063A
(es)
*
|
2004-11-23 |
2007-07-11 |
Celgene Corp |
Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
JP2008544818A
(ja)
*
|
2005-06-30 |
2008-12-11 |
アントフロゲネシス コーポレーション |
胎盤由来コラーゲンバイオ線維を用いた鼓膜の修復
|
AU2006265019B2
(en)
|
2005-06-30 |
2011-10-13 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
US20070021762A1
(en)
*
|
2005-07-13 |
2007-01-25 |
Qing Liu |
Ocular plug formed from placenta derived collagen biofabric
|
US7928280B2
(en)
*
|
2005-07-13 |
2011-04-19 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
ES2485316T3
(es)
|
2005-09-01 |
2014-08-13 |
Celgene Corporation |
Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
|
JP5374153B2
(ja)
*
|
2005-09-02 |
2013-12-25 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
癌の治療のための(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸を使用する方法
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
NZ612132A
(en)
|
2005-10-13 |
2015-01-30 |
Anthrogenesis Corp |
Immunomodulation using placental stem cells
|
KR20080097190A
(ko)
|
2005-12-29 |
2008-11-04 |
안트로제네시스 코포레이션 |
태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
WO2007120669A1
(fr)
*
|
2006-04-13 |
2007-10-25 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Composés tetrahalogénés utilisés comme inhibiteurs d'angiogenèse
|
WO2007136640A2
(fr)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
WO2008021391A1
(fr)
*
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Biomatériau à base de cordon ombilical pour usage médical
|
US20080131522A1
(en)
*
|
2006-10-03 |
2008-06-05 |
Qing Liu |
Use of placental biomaterial for ocular surgery
|
WO2008060377A2
(fr)
|
2006-10-04 |
2008-05-22 |
Anthrogenesis Corporation |
Compositions de tissu du cordon ombilical ou placentaire
|
KR20190112868A
(ko)
|
2006-10-06 |
2019-10-07 |
안트로제네시스 코포레이션 |
천연(텔로펩티드) 태반 콜라겐 조성물
|
JP2010518812A
(ja)
|
2007-02-12 |
2010-06-03 |
アンスロジェネシス コーポレーション |
接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにcd34+、cd45−胎盤幹細胞の濃縮細胞集団
|
EP3103462A1
(fr)
|
2007-02-12 |
2016-12-14 |
Anthrogenesis Corporation |
Traitement de maladies inflammatoires au moyen de cellules souches placentaires
|
WO2008115516A2
(fr)
|
2007-03-20 |
2008-09-25 |
Celgene Corporation |
Dérivés d'isoindoline 4'-o-substitués, compositions renfermant ces dérivés et procédés d'utilisation associés
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
KR20190132556A
(ko)
|
2007-09-28 |
2019-11-27 |
안트로제네시스 코포레이션 |
인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
|
EP2235213A2
(fr)
|
2007-12-20 |
2010-10-06 |
Celgene Corporation |
Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
|
US20090171093A1
(en)
*
|
2007-12-28 |
2009-07-02 |
Yoshio Takeuchi |
3'-Fluoro-5'-hydroxythalidomide and derivatives thereof
|
US20090232796A1
(en)
*
|
2008-02-20 |
2009-09-17 |
Corral Laura G |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
US20110060010A1
(en)
*
|
2008-03-13 |
2011-03-10 |
Tianjin Hemay Bio-Tech Co., Ltd |
Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
|
WO2009111948A1
(fr)
*
|
2008-03-13 |
2009-09-17 |
天津和美生物技术有限公司 |
Sels de 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)pipéridine-2,6-dione ou ses dérivés, leurs polymorphes, procédés de préparation et utilisations associés
|
PL2411506T3
(pl)
|
2009-03-25 |
2019-07-31 |
Celularity, Inc. |
Hamowanie nowotworu z użyciem ludzkich pochodzących z łożyska komórek nk pośrednich i związki immunomodulujące
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
WO2011084968A1
(fr)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
Association d'un composé immunomodulateur et d'une artémisinine ou de son dérivé pour le traitement du cancer
|
ES2730763T3
(es)
|
2010-02-11 |
2019-11-12 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
AU2011352036A1
(en)
|
2010-12-31 |
2013-07-18 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory RNA molecules
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
EP2699909A1
(fr)
|
2011-04-18 |
2014-02-26 |
Celgene Corporation |
Biomarqueurs destinés au traitement de myélome multiple
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
CN113559126A
(zh)
|
2011-06-01 |
2021-10-29 |
人类起源公司 |
利用胎盘干细胞治疗疼痛
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
WO2013182662A1
(fr)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Vaccin
|
EP2867671B1
(fr)
|
2012-06-29 |
2018-10-24 |
Celgene Corporation |
Procédés pour déterminer l'efficacité d'un médicament en utilisant des protéines associées au céréblon
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
US9763983B2
(en)
|
2013-02-05 |
2017-09-19 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
EP2968334A4
(fr)
|
2013-03-14 |
2016-08-03 |
Deuterx Llc |
Dérivés de 3-(oxoquinazolin-3(4h)-yl-4 substitué)-3-deutéro-pipéridine-2,6-dione et des compositions les comprenant et des procédés les utilisant
|
TW201526897A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
WO2015007337A1
(fr)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Procédé de vaccination contre le vih
|
EP3160486B1
(fr)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions et procédés pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
|
WO2016005508A1
(fr)
|
2014-07-11 |
2016-01-14 |
Bionor Immuno As |
Procédé permettant de réduire et/ou de retarder les effets pathologiques du virus de l'immunodéficience humaine i (vih) ou de réduire le risque de développer le syndrome d'immunodéficience acquise (sida)
|
ES2940302T3
(es)
|
2014-08-22 |
2023-05-05 |
Celgene Corp |
Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
|
US10017492B2
(en)
|
2014-10-30 |
2018-07-10 |
Kangpu Biopharmaceuticals, Ltd. |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
CA2984991A1
(fr)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Schema posologique pour un vaccin contre le vih
|
ES2970117T3
(es)
|
2015-06-26 |
2024-05-27 |
Celgene Corp |
Métodos para el tratamiento de sarcoma de Kaposi o linfoma inducido por KSHV usando compuestos inmunomoduladores, y usos de biomarcadores
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
EP3548083A1
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Procédés de modulation de lymphocytes t modifiés par car
|
FI3618842T3
(fi)
|
2017-05-01 |
2023-12-15 |
Juno Therapeutics Inc |
Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä
|
WO2018223101A1
(fr)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles de fabrication et procédés de traitement utilisant une thérapie cellulaire adoptive
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
CA3077325A1
(fr)
|
2017-09-28 |
2019-04-04 |
Celularity Inc. |
Suppression de tumeur a l'aide de cellules tueuses naturelles intermediaires derivees du placenta humain (pink) en combinaison avec un anticorps
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
CA3092037A1
(fr)
|
2018-02-21 |
2019-08-29 |
Celgene Corporation |
Anticorps de liaison a bcma et leurs utilisations
|
KR20210111247A
(ko)
|
2018-11-08 |
2021-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 및 t 세포 조절을 위한 방법 및 조합
|
US10844039B2
(en)
|
2018-11-13 |
2020-11-24 |
Biotheryx, Inc. |
Substituted isoindolinones
|
US20220008465A1
(en)
|
2018-11-16 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
PT3886875T
(pt)
|
2018-11-30 |
2024-06-27 |
Juno Therapeutics Inc |
Métodos para tratamento utilizando terapia celular adotiva
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
CN111499623B
(zh)
*
|
2020-04-01 |
2022-07-08 |
南京缘聚医药科技有限公司 |
一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
|
WO2023250400A1
(fr)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
|
KR20240001071A
(ko)
*
|
2022-06-24 |
2024-01-03 |
주식회사 아이비스바이오 |
신규한 탈리도마이드 유도체 및 이의 제조방법
|
WO2024097905A1
(fr)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur
|